Genexine, Inc. (KOSDAQ:095700)
South Korea
· Delayed Price · Currency is KRW 4,015.00
+30.00 (0.75%)
Apr 1, 2025, 3:30 PM KST
Genexine Revenue
Genexine had revenue of 2.07B KRW in the quarter ending March 31, 2024, with 199.63% growth. This brings the company's revenue in the last twelve months to 5.81B, down -3.50% year-over-year. In the year 2023, Genexine had annual revenue of 4.43B, down -72.57%.
Revenue (ttm)
5.81B
Revenue Growth
-3.50%
P/S Ratio
28.54
Revenue / Employee
67.53M
Employees
86
Market Cap
182.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 4.43B | -11.71B | -72.57% |
| Dec 31, 2022 | 16.14B | -20.69B | -56.18% |
| Dec 31, 2021 | 36.83B | 18.28B | 98.61% |
| Dec 31, 2020 | 18.54B | 7.24B | 64.06% |
| Dec 31, 2019 | 11.30B | 5.05B | 80.80% |
| Dec 31, 2012 | Pro | Pro | Pro |
| Dec 31, 2011 | Pro | Pro | Pro |
| Dec 31, 2010 | Pro | Pro | Pro |
| Dec 31, 2009 | Pro | Pro | Pro |
| Dec 31, 2008 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,547.32B |
| Celltrion | 3,557.30B |
| ALTEOGEN | 102.85B |
| Yuhan | 2,067.79B |
| SK Biopharmaceuticals | 547.60B |
| HLB Co., Ltd. | 51.92B |
| Sam Chun Dang Pharm. | 210.92B |
| PharmaResearch | 350.12B |